Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, VitaNova Life Sciences's Enterprise Value is $10.34 Mil.
VitaNova Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was $0.82 Mil. Therefore, VitaNova Life Sciences's EV-to-OCF for today is 12.68.
The historical rank and industry rank for VitaNova Life Sciences's EV-to-OCF or its related term are showing as below:
VNOV'
s EV-to-OCF Range Over the Past 10 Years
Min: -978 Med: -5.11 Max: 2336.73
Current: 12.68
During the past 10 years, the highest EV-to-OCF of VitaNova Life Sciences was 2336.73. The lowest was -978.00. And the median was -5.11.
VNOV's EV-to-OCF is not ranked
in the Medical Distribution industry.
Industry Median: 7.98
vs VNOV: 12.68
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VitaNova Life Sciences (OTCPK:VNOV) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VitaNova Life Sciences's PE Ratio (TTM) for today is calculated as:
VitaNova Life Sciences's share price for today is $1.38.
VitaNova Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.008.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, VitaNova Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VitaNova Life Sciences EV-to-OCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where VitaNova Life Sciences's EV-to-OCF falls into.
VitaNova Life Sciences's current Enterprise Value is $10.34 Mil.
VitaNova Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VitaNova Life Sciences (VNOV) has a EV-to-OCF of 12.68 as of Sep. 08, 2026.
Is VitaNova Life Sciences' EV-to-OCF too high?
VitaNova Life Sciences' current EV-to-OCF is 12.68. The Medical Distribution industry median EV-to-OCF is 7.98. VitaNova Life Sciences' value of 12.68 is 58.9% above this industry median. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' EV-to-OCF compare to HKPD and COSM?
VitaNova Life Sciences' EV-to-OCF of 12.68 can be compared against companies in the Medical Distribution industry. The industry median EV-to-OCF is 7.98. VitaNova Life Sciences' value of 12.68 is 58.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Distribution company?
The median EV-to-OCF among Medical Distribution companies is 7.98, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VitaNova Life Sciences's current EV-to-OCF of 12.68 is 58.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median EV-to-OCF is 7.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current EV-to-OCF is 12.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current EV-to-OCF of 12.68. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current EV-to-OCF is 12.68 and 58.9% above the Medical Distribution industry median of 7.98. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current EV-to-OCF is 12.68 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VitaNova Life Sciences (VNOV) Overvalued in 2026?
Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued.
The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.
Key valuation signals for VNOV:
EV-to-OCF: 12.68
GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
Industry Position: 58.9% above the Medical Distribution median
No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score
Get the complete analysis for VNOV
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNOV has been successfully added to your 
